Dendritic cell-based immunotherapy of malignant gliomas (Q35922426)

11 August 2017

1 reference

title

Dendritic cell-based immunotherapy of malignant gliomas (English)

1 reference

11 August 2017

1 reference

1 reference

Prahlad Parajuli

1

1 reference

PubMed ID

15493362

11 August 2017

Andrew E Sloan

series ordinal

2

1 reference

11 August 2017

1 January 2004

1 reference

11 August 2017

1 reference

11 August 2017

22

1 reference

11 August 2017

3

1 reference

11 August 2017

405-416

1 reference

Active immunization against cancer with dendritic cells: the near future

11 August 2017

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

Dendritic cells in cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

Dendritic cell vaccines for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

A novel lysosome-associated membrane glycoprotein, DC-LAMP, induced upon DC maturation, is transiently expressed in MHC class II compartment

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

Capture and processing of exogenous antigens for presentation on MHC molecules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

Help for cytotoxic-T-cell responses is mediated by CD40 signalling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

Dendritic cell based tumor vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

Glioma-associated antigen expression in oligodendroglial neoplasms. Tenascin and epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

EGFRvIII as a promising target for antibody-based brain tumor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

Expression of p53 and prognosis in children with malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

Expression of the tumor-rejection antigen SART1 in brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

Expression of the SART3 tumor-rejection antigen in brain tumors and induction of cytotoxic T lymphocytes by its peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

Identifying potential tumor markers and antigens by database mining and rapid expression screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

Analysis of the antibody repertoire of astrocytoma patients against antigens expressed by gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

Glioma-expressed antigen 2 (GLEA2): a novel protein that can elicit immune responses in glioblastoma patients and some controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

Dendritic cells pulsed with tumor extract-cationic liposome complex increase the induction of cytotoxic T lymphocytes in mouse brain tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

The makings of a tumor rejection antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki forest virus-mediated complementary DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus-mediated interleukin-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

Gene therapy of malignant gliomas: a pilot study of vaccination with irradiated autologous glioma and dendritic cells admixed with IL-4 transduced fibroblasts to elicit an immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

Flt3 ligand and granulocyte-macrophage colony-stimulating factor preferentially expand and stimulate different dendritic and T-cell subsets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

Effects of continuous localized infusion of granulocyte-macrophage colony-stimulating factor and inoculations of irradiated glioma cells on tumor regression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

Systemic T cell adoptive immunotherapy of malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

T-cell-directed cancer vaccines: mechanisms of immune escape and immune tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

MHC antigens and tumor escape from immune surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

HLA class I expression on human cancer cells. Implications for effective immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

Generation and characterization of gp100 peptide-specific NK-T cell clones

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

NKT cells - conductors of tumor immunity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200034909

21 January 2018

Identifiers

DOI

10.1081/CNV-200034909

1 reference

11 August 2017

1 reference

PubMed ID

15493362